408 related articles for article (PubMed ID: 33668085)
1. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.
Chourasia M; Koppula PR; Battu A; Ouseph MM; Singh AK
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668085
[TBL] [Abstract][Full Text] [Related]
2. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
Dinda B; Dinda S; Dinda M
Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
[TBL] [Abstract][Full Text] [Related]
6. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
7. An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection.
Bimonte S; Forte CA; Cuomo M; Esposito G; Cascella M; Cuomo A
Drug Des Devel Ther; 2021; 15():4447-4454. PubMed ID: 34737551
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Trans-Epithelial Transport of Green Tea (
Montone CM; Aita SE; Arnoldi A; Capriotti AL; Cavaliere C; Cerrato A; Lammi C; Piovesana S; Ranaldi G; Laganà A
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771162
[TBL] [Abstract][Full Text] [Related]
9. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study.
Tan Q; Duan L; Ma Y; Wu F; Huang Q; Mao K; Xiao W; Xia H; Zhang S; Zhou E; Ma P; Song S; Li Y; Zhao Z; Sun Y; Li Z; Geng W; Yin Z; Jin Y
Bioorg Chem; 2020 Nov; 104():104257. PubMed ID: 32927129
[TBL] [Abstract][Full Text] [Related]
10. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
Henss L; Auste A; Schürmann C; Schmidt C; von Rhein C; Mühlebach MD; Schnierle BS
J Gen Virol; 2021 Apr; 102(4):. PubMed ID: 33830908
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
Mirza MU; Ahmad S; Abdullah I; Froeyen M
Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19.
Wang YQ; Li QS; Zheng XQ; Lu JL; Liang YR
Molecules; 2021 Jun; 26(13):. PubMed ID: 34209485
[TBL] [Abstract][Full Text] [Related]
13. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
Kiba Y; Tanikawa T; Kitamura M
Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
[TBL] [Abstract][Full Text] [Related]
14. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
15. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
16. A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2.
Mhatre S; Naik S; Patravale V
Comput Biol Med; 2021 Feb; 129():104137. PubMed ID: 33302163
[TBL] [Abstract][Full Text] [Related]
17. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
18. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
19. In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2.
Cuesta SA; Mora JR; Márquez EA
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669720
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro.
Kiba Y; Tanikawa T; Hayashi T; Yokogawa T; Sano A; Suzuki R; Kitamura M
J Nat Med; 2024 Jun; 78(3):784-791. PubMed ID: 38512650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
